Bisoprolol
Zebeta (bisoprolol fumarate)
Approved Indications & Off-Label Uses
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Hypertension | Adults | Monotherapy or combination | FDA Approved |
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker with no intrinsic sympathomimetic activity and no significant membrane-stabilizing properties at therapeutic doses. While its only FDA-approved indication in the United States is hypertension, bisoprolol is one of only three beta-blockers (alongside carvedilol and sustained-release metoprolol succinate) recommended by the 2022 AHA/ACC/HFSA guidelines for reducing mortality in heart failure with reduced ejection fraction, based on the landmark CIBIS-II trial. In Europe, bisoprolol holds full regulatory approval for heart failure and stable angina.
Heart failure with reduced ejection fraction (HFrEF) — Bisoprolol 1.25–10 mg daily reduced all-cause mortality by 34% in CIBIS-II (n=2,647; HR 0.66, p<0.0001). Recommended as one of 3 evidence-based beta-blockers by 2022 AHA/ACC/HFSA guidelines. Evidence quality: High.
Rate control in atrial fibrillation/flutter — Used for ventricular rate control per AHA/ACC/HRS guidelines; once-daily dosing and long half-life support sustained 24-hour rate control. Evidence quality: High.
Stable angina pectoris — Bisoprolol 10–20 mg daily has been shown to be at least as effective as atenolol and superior to slow-release nifedipine in reducing transient ischemic episodes. Evidence quality: Moderate.
Perioperative cardiac risk reduction — Used in select high-risk patients undergoing non-cardiac surgery; supported by DECREASE trial data (though later questions about data integrity emerged). Evidence quality: Moderate/Controversial.
Dosing by Clinical Scenario
Adult Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Essential hypertension — initial monotherapy | 5 mg once daily | 5–10 mg once daily | 20 mg once daily | May be taken without regard to meals; BP response seen within 1 week; full effect by 2–4 weeks Some patients may start at 2.5 mg (e.g., those with bronchospastic disease) |
| Hypertension — combination with thiazide | 2.5–5 mg once daily | 5–10 mg once daily | 20 mg once daily | Even very low-dose HCTZ (6.25 mg) is additive with bisoprolol; monitor for orthostatic hypotension |
| Heart failure (HFrEF) — NYHA III–IV (off-label) | 1.25 mg once daily | Titrate q2wk: 2.5 → 3.75 → 5 → 7.5 → 10 mg | 10 mg once daily | Per CIBIS-II protocol (enrolled NYHA III–IV, LVEF ≤35%); patient must be on stable ACEi/ARB + diuretic; target highest tolerated dose AHA/ACC/HFSA 2022 guidelines recommend evidence-based beta-blockers for NYHA I–IV; US tablets available as 5 and 10 mg (lower doses require splitting) |
| Stable angina (off-label) | 5 mg once daily | 10 mg once daily | 20 mg once daily | Titrate to resting HR 55–60 bpm; taper gradually over 1–2 weeks if discontinuing |
| Rate control — atrial fibrillation (off-label) | 2.5–5 mg once daily | 5–10 mg once daily | 20 mg once daily | Long half-life supports sustained 24-h rate control; target resting ventricular rate per guidelines |
Special Populations
| Population | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Renal impairment (CrCl <40 mL/min) | 2.5 mg once daily | Titrate cautiously | Individualize | Half-life approximately tripled; bisoprolol is not significantly dialyzable; no supplemental dose after hemodialysis |
| Hepatic impairment (hepatitis/cirrhosis) | 2.5 mg once daily | Titrate cautiously | Individualize | Half-life prolonged (8.3–21.7 h) and elimination rate more variable in cirrhosis; use with caution |
| Elderly (≥65 years) | No dose adjustment needed based on age alone. Dose reduction only if significant renal or hepatic dysfunction is present. Heart rate reductions may be slightly greater in elderly patients. | |||
Unlike metoprolol and carvedilol, bisoprolol is not metabolized by CYP2D6. This means bisoprolol has no pharmacokinetic interaction with CYP2D6 inhibitors such as fluoxetine, paroxetine, or quinidine. For patients requiring both a beta-blocker and a CYP2D6-dependent antidepressant, bisoprolol may be a pharmacokinetically simpler choice, avoiding the need for dose adjustments or enhanced monitoring that would accompany metoprolol or carvedilol co-prescription.
Pharmacology
Mechanism of Action
Bisoprolol is a highly selective beta-1 adrenergic receptor antagonist with no intrinsic sympathomimetic activity and no significant membrane-stabilizing effects at therapeutic doses. It competitively blocks beta-1 receptors in the heart, reducing heart rate (negative chronotropy), contractility (negative inotropy), and AV conduction velocity (negative dromotropy). These effects lower cardiac output and myocardial oxygen consumption. Bisoprolol also reduces renin release from the juxtaglomerular apparatus, contributing to its antihypertensive action. At therapeutic doses of 5–10 mg, bisoprolol maintains excellent beta-1 selectivity; however, at higher doses (≥20 mg), it begins to inhibit beta-2 receptors in bronchial and vascular smooth muscle, and selectivity diminishes. In heart failure, long-term bisoprolol therapy protects the myocardium from sustained catecholamine stimulation, reduces maladaptive remodeling, and restores beta-receptor sensitivity over time.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Well absorbed; Tmax 2–4 h; bioavailability ~80%; first-pass metabolism ~20%; food does not affect absorption | Highest bioavailability among commonly used beta-blockers; consistent absorption regardless of food intake; once-daily dosing is reliable |
| Distribution | Protein binding ~30% (serum); approximately equally hydrophilic and lipophilic (amphiphilic) | Low protein binding reduces displacement interaction risk; amphiphilic nature allows balanced renal and hepatic elimination; moderate CNS penetration |
| Metabolism | ~50% hepatic; NOT via CYP2D6; metabolites inactive; <2% excreted in feces | CYP2D6 independence eliminates a major class of drug interactions seen with metoprolol and carvedilol; no CYP2D6 poor-metabolizer phenotype concern |
| Elimination | t½ 9–12 h (normal); ~50% unchanged in urine, ~50% as inactive metabolites; t½ ~3x longer if CrCl <40; t½ 8.3–21.7 h in cirrhosis | Long half-life supports once-daily dosing; balanced dual-route elimination means both renal and hepatic impairment independently prolong exposure; not significantly cleared by dialysis |
Bisoprolol Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Headache | 8.8–10.9% | Most common adverse event in hypertension trials; similar incidence to placebo in some studies; usually mild and transient |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Fatigue | 6.6–8.2% | Dose-related; most common reason patients request a medication change; may improve over first weeks of therapy |
| Dizziness | 2.9–3.5% | Related to blood pressure and heart rate reduction; counsel patients to rise slowly from sitting or lying positions |
| Diarrhea | 2.6–3.5% | Dose-related; usually self-limiting; maintain hydration |
| Rhinitis | 2.9–4.0% | Upper respiratory symptoms common; distinguish from coincidental viral URI |
| Cough | ~2.5% | Distinguish from ACE inhibitor-induced cough in patients on combination therapy |
| Arthralgia | 2.2–2.7% | Musculoskeletal complaints; consider alternative etiologies before attributing to bisoprolol |
| Insomnia | 1.5–2.5% | Moderate CNS penetration (amphiphilic); generally less sleep disturbance than highly lipophilic agents like metoprolol |
| Sinusitis | ~2.2% | Dose-related per FDA PI; likely reflects coincidental respiratory tract infections |
| Nausea | 1.5–2.2% | Usually mild; take with food if symptomatic; persistent nausea warrants re-evaluation |
| Asthenia | ~1.5% | Dose-related generalized weakness; overlaps with fatigue; usually improves with dose stabilization |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe bradycardia | Up to 15.2% (HF trials) | Days to weeks after initiation | Reduce dose or hold; atropine for symptomatic bradycardia; temporary pacing if refractory |
| Worsening heart failure | Common during up-titration | First 1–3 months | Increase diuretics; do not advance bisoprolol dose until clinically stable; may need temporary dose reduction |
| Hypotension | 1–5% | First dose or dose increase | Reduce dose; IV fluids if symptomatic; Trendelenburg position |
| AV block (2nd/3rd degree) | Rare | Days to weeks | Discontinue bisoprolol; atropine or isoproterenol; evaluate need for pacing |
| Bronchospasm | Rare at therapeutic doses | Any time; more likely at doses ≥20 mg | Administer beta-2 agonist bronchodilator; reduce or discontinue bisoprolol; cardioselectivity is dose-dependent |
| Rebound angina/MI on abrupt withdrawal | Rare (if tapered properly) | 1–14 days post-discontinuation | Taper over 1–2 weeks; reinstate promptly if rebound symptoms occur |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Bradycardia | <1% | Dose-related; rarely leads to treatment withdrawal in hypertension trials |
| Fatigue / lack of energy | <1% | Dose-related; most patients tolerate this symptom long-term |
| Overall drug-related withdrawals | 3.3% | Lower than placebo (6.8%) in hypertension trials; bisoprolol has one of the lowest discontinuation rates among beta-blockers |
Bisoprolol has one of the most favorable tolerability profiles among beta-blockers. In US placebo-controlled hypertension trials, the overall discontinuation rate for adverse events was actually lower on bisoprolol (3.3%) than on placebo (6.8%). In CIBIS-II, premature treatment withdrawal rates were comparable between bisoprolol and placebo groups. This tolerability profile, combined with once-daily dosing and a pharmacokinetic profile independent of CYP2D6, makes bisoprolol a practical choice for patients who have experienced side effects with other beta-blockers.
Drug Interactions
Bisoprolol is eliminated equally by renal and hepatic pathways and is not metabolized by CYP2D6. This confers a pharmacokinetic interaction profile substantially cleaner than metoprolol or carvedilol. No clinically relevant pharmacokinetic interactions have been documented with thiazide diuretics, cimetidine, or warfarin. The major interaction risks are pharmacodynamic in nature, involving other negative chronotropes and antihypertensives.
The FDA PI specifically confirms no clinically relevant pharmacokinetic interactions between bisoprolol and thiazide diuretics, cimetidine, or warfarin. Bisoprolol had no effect on prothrombin time in patients on stable warfarin doses. This pharmacokinetic simplicity is a distinguishing feature of bisoprolol compared with other beta-blockers in its class.
Monitoring Parameters
- Heart RateEvery visit
RoutineTarget resting HR typically 55–65 bpm for angina/rate control. In heart failure, titrate to highest tolerated dose rather than a specific HR target. Hold or reduce dose if HR <50 bpm with symptoms. - Blood PressureEvery visit
RoutineBP response seen within 1 week of treatment; full effect by 2–4 weeks. BP returns to baseline if bisoprolol is tapered over 2 weeks. - ECGBaseline; repeat if symptomatic
Trigger-basedAssess PR interval at baseline. Repeat if syncope, presyncope, or new palpitations develop. - Blood GlucosePeriodically in diabetic patients
RoutineBeta-1 selectivity makes bisoprolol less likely to mask hypoglycemia or impair glucose recovery than non-selective agents, but caution is still warranted. - Renal FunctionBaseline; periodically if impaired
Trigger-basedCrCl <40 mL/min triples bisoprolol half-life. Reduce starting dose to 2.5 mg and titrate cautiously. Not significantly removed by hemodialysis. - Hepatic FunctionBaseline if liver disease suspected
Trigger-basedHalf-life prolonged to 8.3–21.7 h in cirrhosis with more variable elimination. Start at 2.5 mg and titrate with caution. - Signs of Heart FailureEach visit during HF titration
Trigger-basedWeight gain, peripheral edema, dyspnea. Worsening during up-titration should be managed with diuretic adjustment before reducing bisoprolol.
Contraindications & Cautions
Absolute Contraindications
- Cardiogenic shock
- Overt cardiac failure (decompensated heart failure requiring inotropic support)
- Second- or third-degree AV block (without a functioning pacemaker)
- Marked sinus bradycardia
Relative Contraindications (Specialist Input Recommended)
- Compensated heart failure — bisoprolol is used therapeutically in stable HFrEF (CIBIS-II), but initiation requires careful up-titration with specialist oversight; contraindicated in acutely decompensated failure
- Bronchospastic disease — cardioselectivity diminishes at higher doses (≥20 mg); if essential, start at 2.5 mg with a beta-2 agonist available; avoid in active asthma
- Pheochromocytoma — alpha-blocker must be established first; bisoprolol lacks alpha-blocking activity
- Peripheral vascular disease with symptomatic claudication
Use with Caution
- Diabetes mellitus — may mask tachycardia of hypoglycemia; beta-1 selectivity makes this less pronounced than with non-selective agents
- Thyrotoxicosis — may mask tachycardia; abrupt withdrawal can precipitate thyroid storm
- Renal impairment (CrCl <40) — start at 2.5 mg; half-life tripled
- Hepatic impairment (cirrhosis) — start at 2.5 mg; half-life prolonged and variable (8.3–21.7 h)
- Major surgery — do not routinely withdraw chronic beta-blocker therapy preoperatively
- Cerebrovascular insufficiency — reduced cardiac output may compromise cerebral blood flow
Patients with coronary artery disease should not abruptly discontinue bisoprolol. Exacerbation of angina pectoris, myocardial infarction, and ventricular arrhythmias have been reported following sudden withdrawal of beta-blockers. Taper the dose gradually over approximately 2 weeks. If withdrawal symptoms occur, reinstate bisoprolol promptly. Because coronary artery disease may be unrecognized, it may be prudent to avoid abrupt discontinuation even in patients treated solely for hypertension.
Patient Counselling
Purpose of Therapy
Bisoprolol lowers your blood pressure by slowing your heart rate and reducing the force of each heartbeat. This decreases the workload on your heart. Depending on your condition, it may also be used to protect your heart if you have heart failure, or to control a fast or irregular heartbeat.
How to Take
Take bisoprolol once daily, at the same time each day. You may take it with or without food. Do not crush or chew the tablets. Do not stop taking this medication suddenly — your doctor will gradually reduce your dose if it needs to be discontinued. Continue taking bisoprolol even if you feel well.
Sources
- Zebeta (bisoprolol fumarate) tablets — FDA-approved prescribing information (revised 2011). accessdata.fda.govPrimary US regulatory source for the hypertension indication, dosing, contraindications, adverse reaction incidence data, and pharmacokinetic parameters.
- Bisoprolol fumarate tablets — FDA prescribing information (generic labeling, 2007). accessdata.fda.govCross-reference for adverse reaction table, CYP2D6 independence confirmation, and renal/hepatic impairment dosing adjustments.
- CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13. doi:10.1016/S0140-6736(98)11181-9Landmark trial demonstrating 34% reduction in all-cause mortality and 44% reduction in sudden death with bisoprolol in NYHA III–IV HFrEF (LVEF ≤35%); n=2,647; stopped early for benefit.
- CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90(4):1765–1773. doi:10.1161/01.CIR.90.4.1765First CIBIS trial (n=641) showing a non-significant 20% mortality trend favoring bisoprolol; provided the foundation for the definitive CIBIS-II study.
- Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence (CIBIS-III). Circulation. 2005;112(16):2426–2435. doi:10.1161/CIRCULATIONAHA.105.582320CIBIS-III trial comparing bisoprolol-first vs enalapril-first initiation in HFrEF; both sequences showed comparable outcomes, supporting flexibility in treatment initiation order.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263–e421. doi:10.1016/j.jacc.2021.12.012Current US guideline recommending bisoprolol, carvedilol, or metoprolol succinate as the 3 evidence-based beta-blockers for HFrEF.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA Guideline for the Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2018;71(19):e127–e248. doi:10.1016/j.jacc.2017.11.006US hypertension guideline; beta-blockers are not first-line for uncomplicated hypertension but remain indicated with compelling indications.
- January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update on Atrial Fibrillation. J Am Coll Cardiol. 2019;74(1):104–132. doi:10.1016/j.jacc.2019.01.011Supports use of beta-blockers including bisoprolol for ventricular rate control in atrial fibrillation.
- Haeusler G, Schliep HJ, Schelling P, et al. High beta-1 selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol. J Cardiovasc Pharmacol. 1986;8(Suppl 11):S2–S15. doi:10.1097/00005344-198511001-00002Foundational review of bisoprolol’s exceptional beta-1 selectivity, balanced renal-hepatic elimination, and CYP2D6-independent metabolism.
- Leopold G. Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmacol. 1986;8(Suppl 11):S16–S20. doi:10.1097/00005344-198511001-00004Established the dual renal-hepatic elimination pathway (~50/50), 80% bioavailability, and 9–12 hour half-life that underpin once-daily dosing.
- Casadei B, Conway J, Peart S, Sleight P. The effect of bisoprolol on heart rate and lung function in patients with chronic obstructive pulmonary disease. Eur Heart J. 1992;13(suppl A):38–42. Demonstrated that bisoprolol at therapeutic doses (5–10 mg) has minimal effect on airway resistance, supporting its use in patients with mild COPD.
- Castagno D, Jhund PS, McMurray JJV, et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the CIBIS-II trial. Eur J Heart Fail. 2010;12(6):607–616. doi:10.1093/eurjhf/hfq038Post-hoc analysis of CIBIS-II confirming that bisoprolol’s mortality benefit is maintained across all eGFR categories; renal impairment should not preclude its use.